<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03102658</url>
  </required_header>
  <id_info>
    <org_study_id>UMCN-AKF 16.02</org_study_id>
    <nct_id>NCT03102658</nct_id>
  </id_info>
  <brief_title>Micafungin Pharmacokinetics in Obese Patients</brief_title>
  <acronym>MICADO</acronym>
  <official_title>Micafungin (Mycamine®) Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (MICADO).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Because micafungin is generally well tolerated and appears to have limited interaction with&#xD;
      other drugs, it is a potential important agent in the treatment of invasive fungal&#xD;
      infections. Although micafungin is approved for the treatment of invasive candidiasis, dosing&#xD;
      guidelines for micafungin in (morbidly) obese patients are not available. Subsequently, the&#xD;
      pharmacokinetic profile of micafungin (as well as other echinocandins) in this specific&#xD;
      patient population is still largely unknown.&#xD;
&#xD;
      To build a valid pharmacokinetic model, obese patients with a BMI ≥ 40 undergoing endoscopic&#xD;
      gastric bypass surgery will receive a single dose of 100 mg or 200mg micafungin (besides&#xD;
      standard anti-bacterial prophylaxis) and samples for a pharmacokinetic curve will be taken.&#xD;
      These PK-values can then be compared to the PK in a normal-weight group which will receive&#xD;
      100mg micafungin&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obese patients with a BMI ≥ 40 kg/m2 undergoing endoscopic gastric bypass surgery will&#xD;
      receive a 100 mg or a 200mg dose of micafungin. A PK curve will be determined after&#xD;
      administration at t=0.5, 0.95, 1.25, 1.5, 2, 4, 8, 12, 24, and (if feasible) 48 hours post&#xD;
      infusion. Blood samples (4 mL) on PK days will be taken to obtain at least 2.0 mL of plasma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Micafungin concentration in plasma to examen the area under the plasma concentration versus time curve (AUC0-48)</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>The exposure to micafungin in obese will be compared with that in non-obese subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long-term exposure to micafungin after repeated dose</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Predict long-term exposure (AUC0-tau) after repeated dosing by popPK modeling and simulation.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Morbid Obesity</condition>
  <arm_group>
    <arm_group_label>Obese subjects 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 subjects with a BMI&gt;40kg/m2 will receive 100mg Micafungin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese subjects 200mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 subjects with a BMI&gt;40kg/m2 will receive 200mg Micafungin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-obese subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 non obese subjects with a BMI &gt;18.5 and &lt;25 kg/m2 will receive 100mg Micafungin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micafungin</intervention_name>
    <description>Administration of study drug</description>
    <arm_group_label>Obese subjects 100mg</arm_group_label>
    <arm_group_label>Obese subjects 200mg</arm_group_label>
    <arm_group_label>non-obese subjects</arm_group_label>
    <other_name>Mycamine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Subjects BMI:&#xD;
&#xD;
               -  obese groups: subject must have a BMI &gt; 40 kg/m2 at the time of inclusion,&#xD;
&#xD;
               -  non-obese group: subject must have a BMI ≥18.5 and &lt; 25kg/m2 at the time of&#xD;
                  inclusion.&#xD;
&#xD;
          2. Subject is at least 18 of age on the day of screening and not older than 65 years of&#xD;
             age on the day of dosing;&#xD;
&#xD;
          3. If a woman, is neither pregnant nor able to become pregnant and is not nursing an&#xD;
             infant;&#xD;
&#xD;
          4. Subject is able and willing to sign the Informed Consent before screening evaluations.&#xD;
&#xD;
             For the non-obese subjects the following additional exclusion criteria apply:&#xD;
&#xD;
          5. Subject is in good age-appropriate health condition as established by medical history,&#xD;
             physical examination, electrocardiography, results of biochemistry, hematology and&#xD;
             urinalysis testing within 4 weeks prior to study drug administration. Results of&#xD;
             biochemistry, hematology and urinalysis testing should be within the laboratory's&#xD;
             reference ranges. If laboratory results are not within the reference ranges, the&#xD;
             subject is included based on the investigator's judgment that the observed deviations&#xD;
             are not clinically relevant. This should be clearly recorded;&#xD;
&#xD;
          6. Subject has a normal blood pressure and pulse rate, determined by the investigator;&#xD;
&#xD;
          7. Subject does not smoke more than 10 cigarettes, 2 cigars, or 2 pipes per day for at&#xD;
             least 3 months prior to study drug administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Documented history of sensitivity to medicinal products or excipients similar to those&#xD;
             found in the micafungin preparation;&#xD;
&#xD;
          2. History of, or known abuse of drugs, alcohol or solvents (up until a maximum of three&#xD;
             months before study drug administration);&#xD;
&#xD;
          3. Inability to understand the nature of the trial and the procedures required;&#xD;
&#xD;
          4. Use of medication that has known interaction with study drug as determined by the&#xD;
             investigator up to 4 weeks prior to study drug administration.&#xD;
&#xD;
             For the non-obese subjects the following additional exclusion criteria apply:&#xD;
&#xD;
          5. Evidence of organ dysfunction or any clinically significant deviation from normal in&#xD;
             physical examination, vital signs or clinical laboratory determinations;&#xD;
&#xD;
          6. Clinical relevant liver enzymes (alkaline phosphatase, alanine aminotransferase,&#xD;
             aspartate transaminase) abnormalities at screening;&#xD;
&#xD;
          7. Donation of blood or plasma to a blood bank or in a clinical study (except a screening&#xD;
             visit) within 4 weeks prior to study drug administration;&#xD;
&#xD;
          8. Blood transfusion within 8 weeks prior to study drug administration;&#xD;
&#xD;
          9. Inability to be venipunctured and/or tolerate venous access;&#xD;
&#xD;
         10. Relevant history or presence of pulmonary disorders (especially COPD), cardiovascular&#xD;
             disorders, neurological disorders (especially seizures and migraine), psychiatric&#xD;
             disorders, gastro-intestinal disorders, renal disorders, hepatic disorders (Child-Pugh&#xD;
             B or C), hormonal disorders (especially diabetes mellitus), coagulation disorders;&#xD;
&#xD;
         11. Any other sound medical, psychiatric and/or social reason as determined by the&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger Brüggemann, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Antoniusziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboudumc CRCN</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/30649375/</url>
    <description>paper</description>
  </link>
  <results_reference>
    <citation>Wasmann RE, Smit C, Ter Heine R, Koele SE, van Dongen EPH, Wiezer RMJ, Burger DM, Knibbe CAJ, Brüggemann RJM. Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults. J Antimicrob Chemother. 2019 Apr 1;74(4):978-985. doi: 10.1093/jac/dky554.</citation>
    <PMID>30649375</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>January 5, 2017</study_first_submitted>
  <study_first_submitted_qc>March 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2017</study_first_posted>
  <last_update_submitted>October 16, 2020</last_update_submitted>
  <last_update_submitted_qc>October 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Micafungin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

